LENSAR, Inc. (LNSR)Healthcare | Medical Devices | Orlando, United States | NasdaqCM
5.82 USD
-0.19
(-3.161%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 4:33 a.m. EDT
The investment case for LENSAR is currently paralyzed by the collapse of its Alcon acquisition strategy. While the company boasts impressive profit margins (51%) and a fortress balance sheet with minimal debt, the failure of the deal has triggered a brutal re-rating, sending the stock down nearly 40% year-over-year and erasing the massive 179% rally seen in the prior year. The business fundamentals remain sound, but the market is pricing in significant uncertainty regarding future growth without the strategic partner. With revenue contracting and no dividend to provide income, the stock offers no immediate catalyst. The options market reflects this stalemate, with heavy put open interest capping upside potential. Until there is clarity on a new strategic path or organic growth acceleration, the risk-reward profile remains neutral-to-negative. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.058316 |
| AutoETS | 0.076485 |
| MSTL | 0.100806 |
| AutoARIMA | 0.248607 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 2.39 |
| Ljung-Box p | 0.022 |
| Jarque-Bera p | 0.788 |
| Excess Kurtosis | -0.10 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 10.474 |
| Revenue per Share | 4.787 |
| Market Cap | 71,478,800 |
| Forward P/E | -8.20 |
| Beta | 0.87 |
| Profit Margins | 50.94% |
| Website | https://www.lensar.com |
As of July 11, 2026, 4:33 a.m. EDT: Speculators are positioning for a range-bound outcome rather than a breakout. Call volume is heavily skewed toward out-of-the-money strikes (7.5 and 10.0), suggesting a hope for a recovery to the 2025 highs, yet put open interest is significantly higher at the 7.5 strike. This 'iron condor' style positioning indicates the market expects volatility but doubts a decisive move in either direction, effectively betting against a sharp crash while hoping for a modest bounce.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.5341085 |
| Address1 | 2,800 Discovery Drive |
| All Time High | 17.31 |
| All Time Low | 1.8 |
| Ask | 5.87 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Daily Volume10 Day | 174,040 |
| Average Daily Volume3 Month | 81,739 |
| Average Volume | 81,739 |
| Average Volume10Days | 174,040 |
| Beta | 0.871 |
| Bid | 4.34 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 0.892 |
| City | Orlando |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.82 |
| Current Ratio | 2.382 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 6.1679 |
| Day Low | 5.805 |
| Debt To Equity | 10.474 |
| Display Name | LENSAR |
| Earnings Call Timestamp End | 1,778,243,400 |
| Earnings Call Timestamp Start | 1,778,243,400 |
| Earnings Timestamp | 1,778,243,400 |
| Earnings Timestamp End | 1,786,019,400 |
| Earnings Timestamp Start | 1,786,019,400 |
| Ebitda | -20,588,000 |
| Ebitda Margins | -0.35679 |
| Enterprise To Ebitda | -3.561 |
| Enterprise To Revenue | 1.27 |
| Enterprise Value | 73,310,192 |
| Eps Current Year | -0.08 |
| Eps Forward | -0.71 |
| Eps Trailing Twelve Months | -0.55 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.7881 |
| Fifty Day Average Change | 0.031900406 |
| Fifty Day Average Change Percent | 0.005511378 |
| Fifty Two Week Change Percent | -53.41085 |
| Fifty Two Week High | 13.425 |
| Fifty Two Week High Change | -7.605 |
| Fifty Two Week High Change Percent | -0.56648046 |
| Fifty Two Week Low | 5.06 |
| Fifty Two Week Low Change | 0.7600002 |
| Fifty Two Week Low Change Percent | 0.15019767 |
| Fifty Two Week Range | 5.06 - 13.425 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,601,645,400,000 |
| Float Shares | 8,675,051 |
| Forward Eps | -0.71 |
| Forward P E | -8.197184 |
| Free Cashflow | -22,666,876 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 150 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.45714 |
| Gross Profits | 26,379,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.21529 |
| Held Percent Institutions | 0.5201 |
| Implied Shares Outstanding | 12,281,581 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida. |
| Long Name | LENSAR, Inc. |
| Market | us_market |
| Market Cap | 71,478,800 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_41699596 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | 29,397,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 71,785,840 |
| Number Of Analyst Opinions | 2 |
| Open | 5.97 |
| Operating Cashflow | -12,164,000 |
| Operating Margins | -0.15892 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 888 536 7271 |
| Previous Close | 6.01 |
| Price Eps Current Year | -72.75 |
| Price Hint | 2 |
| Price To Book | 6.524664 |
| Price To Sales Trailing12 Months | 1.2387148 |
| Profit Margins | 0.50944 |
| Quick Ratio | 1.049 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.19 |
| Regular Market Change Percent | -3.1614 |
| Regular Market Day High | 6.1679 |
| Regular Market Day Low | 5.805 |
| Regular Market Day Range | 5.805 - 6.1679 |
| Regular Market Open | 5.97 |
| Regular Market Previous Close | 6.01 |
| Regular Market Price | 5.82 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 19,845 |
| Return On Assets | -0.22584999 |
| Return On Equity | 3.6254501 |
| Revenue Growth | -0.052 |
| Revenue Per Share | 4.787 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 10 |
| Shares Outstanding | 12,281,581 |
| Shares Percent Shares Out | 0.041199997 |
| Shares Short | 505,438 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 871,803 |
| Short Name | LENSAR, Inc. |
| Short Percent Of Float | 0.056999996 |
| Short Ratio | 4.52 |
| Source Interval | 15 |
| State | FL |
| Symbol | LNSR |
| Target High Price | 10.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 8.5 |
| Target Median Price | 8.5 |
| Total Cash | 13,495,000 |
| Total Cash Per Share | 1.115 |
| Total Debt | 2,574,000 |
| Total Revenue | 57,704,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.55 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.31725 |
| Two Hundred Day Average Change | -3.49725 |
| Two Hundred Day Average Change Percent | -0.37535217 |
| Type Disp | Equity |
| Volume | 19,845 |
| Website | https://www.lensar.com |
| Zip | 32,826 |